Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EXCLUSIVE: Charlie Sheen's Doctor Gives HIV Health Update: 'He's on a New Experimental Medication'
Now, Huizenga praises Sheen's advocacy, telling ET, "He is living up to his promise to use his celebrity status not only to alert the country and the world of these incredible needs for better HIV treatment -- especially in the over two-thirds or three-quarters that aren't getting proper HIV medication -- but he's also kind of pioneering the way with new treatments."
"I'm really proud of everything he's done and his continued commitment to HIV education," he said.
http://www.etonline.com/news/192714_exclusive_charlie_sheen_doctor_gives_hiv_health_update/
Just waiting for news...
I emailed investors' relations requesting an update from management regarding their clinical studies.
I don't think they know anything more than the rest of us...they're just stating that the shorts have decreased which is typically good news for a stock's SP to trend up.
Let the adding begin.
http://www.engelwooddaily.com/cytodyn-incorporated-otcmktscydy-shorted-shares-decreased-by-5-1/418685/
CYTODYN INCORPORATED (OTCMKTS:CYDY) Shorted Shares Decreased By 5.1%
We've picked up 4 followers on this board alone since yesterday. We are slowly getting out there. These next 2 weeks should be exciting.
I disagree with you saying there's no positive catalysts on the horizon. We can hear about ODD, last patient injected for adjunct, first for mono, potential licensing deal, etc.
Do you have any position in CYDY currently?
What are your thoughts on the latest PR about SeeThruEquity?
SeeThruEquity Initiates Coverage on CytoDyn Inc. (CYDY) with a Price Target of $3.40
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of CytoDyn Inc. (CYDY).
The report is available here: CYDY Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Nice Chump
Could be. May also be that some long term investors are restless and they're selling off.
As am I. I thought ASM + Charlie publicity would have been enough to get a whole new base of investors and push this thing over $2. Ultimately, the end game for investors (long term of course) is a BO or BLA submission. Science hasn't changed and this will be the new standard of care for a $10+ billion market assuming approval.
Other companies may do it another way; however, Dr. P has stated on numerous occasions that he will only announce first and last patient injected. A catalyst I could see in the near future could be last patient injected for adjunct phase III. Outside of that, not much else.
Management only reports on first and last patient being injected. Dilution is inevitable without a partnership. But like I asked - what's a few million more shares being issued for a product that is targeting a multibillion dollar market? It's a shame that trials have been delayed this much, but this is not a short term stock flip unless there's a buyout.
Pretty much sums up my sentiment on this stock. The only thing would be missing the boat if there is a buyout which is very possible. I'm still very optimistic and in it for the long haul. Even with more dilution though - what's a few million shares for a product targeting a multibillion dollar market?
PRO-140 antibody injections maintain viral suppression in phase 2 study
Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in people with viral suppression, according to a study presented at the ASM Microbe 2016 meeting last week in Boston.
HIV uses two co-receptors – CCR5 and CXCR4 – along with the CD4 cell surface receptor to enter cells. PRO 140 is a humanised monoclonal antibody that works by blocking CCR5, thereby preventing HIV from getting into cells and replicating. About 70% of people with HIV in the US, and up to 90% of newly diagnosed people, have CCR5-tropic virus.
Previous studies showed that a single intravenous injection of PRO 140 dramatically reduced HIV levels, and weekly subcutaneous (under the skin) injections reduced viral load significantly more than placebo. Results to date suggest that PRO 140 does not negatively affect normal immune functions mediated by CCR5.
PRO 140 was initially developed by Progenics but was acquired by CytoDyn in 2012. Clinical trial data on PRO 140 have not been presented at scientific conferences or in medical journals for several years, but CytoDyn has issued numerous press releases tracking its progress.
Paul Maddon, a scientific advisor at CytoDyn, presented findings from a phase 2b trial of PRO 140 as maintenance therapy for people who had achieved viral suppression on standard combination ART.
The CD01 study included 39 HIV-positive adults with exclusively CCR5-tropic HIV (according to the Trofile DNA Co-receptor Tropism Assay), viral load below 40 copies/ml on a stable ART regimen and a CD4 T-cell count above 350 cells/mm3. More than 90% were men with a median age of 55 years.
All participants in this open-label study switched, with one week of overlap, from their ART regimen to weekly 350mg subcutaneous injections of PRO 140 monotherapy for up to 12 weeks. Those who experienced viral rebound restarted ART.
Among the 28 patients in the cohort assessing longer-term treatment, 15 people who maintained viral suppression for 12 weeks were trained to self-administer their shots and allowed to continue PRO 140 maintenance therapy for an additional 108 weeks in an extension phase. In this group 87% were men, 20% were non-white, the median age was 55, the median CD4 count was 586 cells/mm3 and they had been diagnosed with HIV for a median of 13 years.
Of these 15 participants, 10 are still on PRO 140 without ART after more than a year – and in some cases approaching two years. Among people tested with a single-copy HIV RNA assay, the lowest median viral load was 0.4 copies/ml.
Of the remaining participants, four experienced virological failure (two consecutive measurements of > 400 copies/ml) and restarted ART, while one relocated and left the study with an undetectable viral load at 47 weeks.
Participants did not show evidence of drug resistance, those with virological failure did not experience a change in HIV tropism – allowing their virus to enter using CXCR4 instead of CCR5 co-receptors – and no-one developed antibodies against PRO 140. All participants who restarted ART regained full viral suppression.
PRO 140 was generally safe and well tolerated. While overall adverse events were common (more than 90% in the extension phase), there were no drug-related serious adverse events or treatment discontinuations for this reason. All drug-related adverse events were local injection site reactions, usually mild or moderate.
"For [more than] one year, weekly PRO 140 subcutaneous 350mg provided full viral suppression, was well tolerated, and enabled the avoidance of potential toxicity of ART while preserving drug options", the researchers concluded. "These results support further development of PRO 140 SC as a simple, long-acting, single-agent maintenance therapy after initial ART in selected HIV-1 patients."
They noted that the extension phase of the study is ongoing, with a plan to further extend PRO 140 monotherapy beyond 120 weeks for patients with continued viral suppression.
insert-text-here
Nice article there. The word is slowly starting to spread.
I got the same impression. He was almost too calm and collected when he said it. Time to wait and see.
I'm pretty good at ignoring the nonsense.
I must say that I was intrigued by chumps post yesterday. I'd love to know how accurate his information is. Hasn't seemed to be misleading thus far.
Some interesting adding going on today. Thoughts on today's volume...?
Day traders hopping back in? Word finally spreading? Something else?
Making the front page of a lot of sites:
http://m.medicalxpress.com/news/2016-06-weekly-standalone-treatment-hiv-patients.html
http://finance.yahoo.com/news/stocknewsnow-com-publishes-snnlive-video-173900730.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZAMzNWZjODlwYm1sam5kBGcDZFhWcFpEeHVjejQwWkRRM05XRTBPQzAxTXpjNUxUTmhNV0l0T0RNNE15MWlNREpqWlRRd1l6WmtaV1k4Wm1sbGJHUStZM2xrZVE9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA0NZRFk-?.tsrc=applewf
For those interested in viewing the presentation that Dr. Nader did at the MicroCap conference.
Just watched the Today Show and Charlie spoke very highly of the trial he was on - no side effects or pill fatigue. It's a shame he didn't mention the company or drug by name, but I'm not phased by the recent short-term drop in SP. It's going to take some time and patience here, but the science hasn't changed.
Charlie talking about PRO 140:
http://www.usatoday.com/story/life/people/2016/06/21/charlie-sheen-gives-today-status-update/86171076/
He's now taking part in an FDA-sanctioned drug trial, in which he receives one injection per week rather than daily pills and must adhere to a strict schedule, and the new treatment seems to be agreeing with him. "The change isn't just physical but psychological and emotional," he told Lauer. "There's no depression. There are no shades of dementia. What I'm doing now is the future of treatment."
Gilead can play dumb even though they've already said CytoDyn is a legitimate threat to their HIV revenue stream:
http://marketstatsanalytics.com/gild_proscons3.html
In addition to the well-known presence of several competitors in the HCV market, a significant threat could arise in the HIV market if a major biotech firm acquires one of the small firms now working on alternatives to the HAART treatments sold by Gilead Sciences. An example is the treatment named PRO140, developed by CytoDyn
People are fickle and impulsive. It's sometimes easy to ignore what the long-term benefits of this stock could hold when you focus on the short-term effects of how its trading. I would love to see some PR on the last patient for either trial having been injected though.
That's where I'm at too. Minus the bag part though.
Fascinating how a celebrity does more for the SP then presentatiing at the largest medical conference. The ASM conference is wrapping today, so I'm sure we'll see some PR on it soon. Coupled with Charlie going on the Today Show, I expect we'll see a broad new base of investors that will push the SP up. I expected more volume today, but it looks like it will take time for the news to spread.
I believe the migraines were attributable to the anti-retrovirals he was on before PRO 140.
I was hoping that they found PRO 140 was able to address another disease during their clinical trials. The CCR5 receptor is involved in many other diseases including and not limited to: GvHD, West Nile Virus, atherosclerosis, certain cancers, and others.
We shall see soon enough!
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057285/
I'm hoping they found another application outside of HIV and GvHD treatment.
Or for how much.
I'm not worried either. Still dumbfounded at the fact that this is dropping when we have a drug (pending approval) that will replace the current standard of care for a market that is $20+ billion and growing.
Pretty obscene this thing would dip in to the red today leading up to all the exposure we're going to be getting next week. Excited to see what happens Monday morning!
Some new names here on the board and a lot more chatter. I expect this thing to have just as much volume tomorrow as it did today.
Shorts are gunna be in a panic
Run baby run!
Nice. Looks like we have some momentum going here, hopefully you get the rest filled soon!
We've received a few grants from the NIH; however, it would have to be one hell of a grant to help fund 2-phase III clinical trials for HIV. Let alone all the GVHD trials and if a breast/prostate cancer application is explored further.
Today is looking very similar to yesterday with an early dip, followed by a slow, steady climb.
If I'm not mistaken, I think this was actually addressed on the last conference call. It's nice to know that it wasn't due to virological failure. I know the CCR5 tropism can morph to a different subtype of the virus. I wonder if the fact that PRO 140 has the ability to achieve full virological suppression that it can actually slow or stop the morphisms altogether. Maybe this is one of their aces in the hole.
Yup! Looks like those major sellers from a couple months back are done (or at least for the moment). Smaller than I anticipated volume wise today, but I like that it was steady adding instead of a huge spike. Very exciting times here!
Not sure. He's on the monotherapy - so the most he should be experiencing is irritation around the injection site. With the combinational therapy there could be nausea, vomitting, etc. because patients are still taking the other anti-retrovirals that cause them. For the patients sake, I hope the monotherapy trials finishes first. It would also put more pressure on big pharma's to gobble CytoDyn up because we would effectively eliminate the need for all the other anti-retrovirals.